- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial2019 | Central Library of Charles University, Faculty of Medicine in Hradec Králové
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma2018 | First Faculty of Medicine
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial2022 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment C16010Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. C16021Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: C16010Publication without faculty affiliation